After a new deadly and a rather contagious variant of the Coronavirus was reported by the scientists in South Africa, the world has gone into a crisis aversion mode once again. WHO last Friday designated SARS-CoV-2 variant B.1.1.529 as a ‘variant of concern’ and named it “Omicron”. The entire continent of Europe which was already seeing a huge influx of positive cases along with the United States of America (North America) has been caught off guard. Now, the newly, mutated and dangerous virus is coming for them and as we have seen before, you’d rather want a COVAXIN jab than a Pfizer jab when the situation turns dire.
The Western world and its petulance for Pfizer
The one thing common in both continents is that they have been big proponents of mRNA-developed vaccines- Pfizer to be specific. And it appears that their rather subservient attitude towards the big pharmaceutical giants is making them pay dearly.
Straight off the bat, the two mRNA vaccines are incredibly expensive, which even the poor Americans or Europeans cannot afford, forget the supposed third world countries of Africa or Asia.
Moreover, the mRNA vaccines and their manufacturing parent companies have earned no fans for their shadowy practices. They have inserted dictatorial clauses in the contract to shrug off any responsibility for the adverse effects of the vaccine and have openly falsified the data.
Pfizer’s faulty vaccines and compromised R&D process:
As reported extensively by TFI, British Medical Journal (The BMJ) recently published an investigative report titled ‘Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial’, which raises some really serious questions regarding the Pfizer vaccine trial data.
As per the British Medical Journal (BMJ), Brook Jackson, who was employed at the research organisation – Ventavia Research Group, alleged that Pfizer falsified data, unblinded patients, employed inadequately trained vaccinators, and was also slow in responding to the adverse incidents reported in Pfizer’s pivotal phase III trial.
Recent research by Western Reserve University and Brown University has revealed that COVID-19 antibodies produced by the Pfizer vaccine decreased more than 80 percent in senior nursing home residents and their caregivers within six months after receiving their second dose.
Earlier this month, France’s public health authority casting aspersions over the efficacy of the Moderna covid vaccine recommended that people under 30 should not get jabbed with the US-developed vaccine.
Meanwhile, a German newspaper named Berliner Zeitung has insinuated that the deluge of heart-related problems in professional athletes across the globe could be a potentially harmful side effect of mRNA-based vaccines.
Americans want alternatives — alternatives such as COVAXIN
An article on American Bazaar written by Craig Snyder, says that COVAXIN is the best vaccine out there but is unfortunately not available to Americans. Many people in the USA are refusing to take the mRNA vaccines, but they don’t agree with being called ‘anti-vaxxers’.
They just want a choice beyond mRNA vaccines, a choice that COVAXIN provides. Unfortunately, it is only the mRNA vaccines of Pfizer and Moderna that have been so far shoved down the throats of common Americans.
The Bharat Biotech developed vaccine can help countries like the USA win over their vaccine-hesitant populace which can help them beat variants like Omicron.
COVAXIN was developed using old, reliable methods:
COVAXIN has been manufactured using a live virus, that is, using a manufacturing process that has been used in childhood vaccines for polio and other diseases, for decades. Succinctly put, COVAXIN is the best vaccine out there to address the hesitancy of millions of Americans with respect to the mRNA vaccines.
Moreover, the efficacy of COVAXIN is unrivaled. Compared to other publicly available data, it shows the best neutralization titers against variants of concern – Delta and Beta, and even outperforms on those measures compared with people previously infected with the original COVID-19 strain.
Superior efficacy and cheaper storage
Immediately after receiving a much-delayed Emergency Use Authorization (EUA) approval from the WHO, even the highly dubious medical journal Lancet had stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid-19 infections, as demonstrated by the phase 3 data.
The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus. More importantly, the vaccine showed 93.4 per cent efficacy in severe symptomatic cases. The medical journal added that no severe-vaccine-related deaths or adverse events were recorded during the randomized trials.
When we talk about cost of the vaccines, Moderna costs around $32 to $37 and Bharat Biotech’s COVAXIN costs merely $3 to $5. When we talk about compatibility, COVAXIN is more storage-friendly than other vaccines. For instance, Pfizer needs to be kept in extremely cold temperatures of minus 70 degrees Celsius, the cost of which may go into billions, whereas COVAXIN requires only 2-8 degrees Celsius cold chain, which is much more viable for warm, developing and underdeveloped nations.
What is the new virus strain?
The new virus strain has been detected in South Africa, Hong Kong, Israel, and Botswana and it wouldn’t be a hyperbole to suggest that it would have already entered North America and Europe.
Speaking about the deadliness of the variant, WHO has remarked, “Omicron’s actual risks are not understood yet. But early evidence suggests it carries an increased risk of re-infection compared with other highly transmissible variants,”
Ahead of the busy festival season in the West, the European countries are pondering going into lockdown mode for the umpteenth time, which in turn will affect the global economy. Only if these countries had gotten rid of their racist blinkers and allowed vaccines like Covaxin, the situation would have not turned so dire.